Race-based therapy for hypertension: possible benefits and potential pitfalls

References

• Royal CD, Dunston GM. Changing the paradigm from ‘race’ to human genome variation. Nat. Genet.36(11 Suppl.), S5–S7 (2004).
   PubMed Web of Science ®Google Scholar
• Kittles RA, Weiss KM. Race, ancestry, and genes: implications for defining disease risk. Annu. Rev. Genomics Hum. Genet.4, 33–67 (2003).
   PubMedGoogle Scholar
• Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation117(4), E25–E146 (2008).
   PubMed Web of Science ®Google Scholar
• Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension44(4), 398–404 (2004).
   PubMed Web of Science ®Google Scholar
• Clark LT, Ferdinand KC, Flack JM et al. Coronary heart disease in African–Americans. Heart Dis.3(2), 97–108 (2001).
   PubMedGoogle Scholar
• Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States. JAMA290(2), 199–206 (2003).
   PubMed Web of Science ®Google Scholar
• Flack JM, Ferdinand KC, Nasser SA. Epidemiology of hypertension and CVD in African–Americans. J. Clin. Hypertens. (Greenwich)5(1 Suppl. 1), 5–11 (2003).
   PubMedGoogle Scholar
• Xiangrong L, Shengxu L, Eralp U et al. Childhood adiposity as a predictor of cardiac mass in adulthood. Circulation110(22), 3488–3492 (2004).
   PubMedGoogle Scholar
• Wattigney WA, Webber LS, Srinivasan SR, Berenson GS. The emergence of clinically abnormal levels of CVD risk factor variables among young adults: the Bogalusa Heart Study. Prevent. Med.24(6), 17–626 (1995).
   Google Scholar
• Douglas JG, Barkis GL, Epstein M et al. Management of high blood pressure in African–Americans: consensus statement of the Hypertension in African–Americans Working Group of the International Society on Hypertension in Blacks. Arch. Intern. Med.163(5), 525–541 (2003).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. The JNC 7 report. JAMA289(19), 2560–2672 (2003).
   PubMed Web of Science ®Google Scholar
• Racial/ethnic and socioeconomic disparities in multiple risk factors for heart disease and stroke – United States, 2003. MMWR Morb. Mortal. Wkly Rep.54(5), 113–117 (2005).
   PubMedGoogle Scholar
• Jones DW, Chambless LE, Folsom AR et al. Risk factors for coronary heart disease in African–Americans: the atherosclerosis risk in communities study. Arch. Intern. Med.162(22), 2565–2571 (2002).
   PubMedGoogle Scholar
• Winkleby MA, Kraemer HC, Ahn DK, Varady AN. Ethnic and socioeconomic differences in CVD risk factors: findings for women from the Third National Health and Nutrition Examination Survey, 1988–1994. JAMA280(4), 356–362 (1998).
   PubMed Web of Science ®Google Scholar
• Hertz RP, Unger AN, Cornell J et al. Racial disparities in hypertension prevalence, awareness, and management. Arch. Intern. Med.165(18), 2098–2104 (2005).
   PubMed Web of Science ®Google Scholar
• Douglas JG, Ferdinand KC, Bakris GL et al. Barriers to blood pressure control in African–Americans. Postgrad. Med.112(4), 51–70 (2002).
   PubMed Web of Science ®Google Scholar
• Nesbitt SD. Hypertension in Black patients: special issues and considerations. Curr. Cardiol. Rep.6(6), 416–420 (2004).
   PubMedGoogle Scholar
• Knox SS, Hausdorff J, Markovitz JH. Reactivity as a predictor of subsequent blood pressure: racial differences in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Hypertension40(6), 914–919 (2002).
   PubMed Web of Science ®Google Scholar
• Light KC, Turner JR, Hinderliter AL, Sherwood A. Race and gender comparisons: I. Hemodynamic responses to a series of stressors. Health Psychol.12(5), 354–365 (1993).
   PubMed Web of Science ®Google Scholar
• Saab PG, Llabre MM, Hurwitz BE et al. Myocardial and peripheral vascular responses to behavioral challenges and their stability in Black and White Americans. Psychophysiology29(4), 384–397 (1992).
   PubMed Web of Science ®Google Scholar
• Stein CM, Lang CC, Nelson R et al. Vasodilatation in Black Americans: attenuated nitric oxide-mediated responses. Clin. Pharmacol. Ther.62(4), 436–443 (1997).
   PubMedGoogle Scholar
• Li R, Lynd D, Lapu-Bula R et al. Relation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function, and blood pressure in African–Americans. Am. J. Hypertens.17(7), 560–567 (2004).
   PubMed Web of Science ®Google Scholar
• Hinderliter AL, Sager AR, Sherwood A, Light KC, Girdler SS, Willis PW 4th. Ethnic differences in forearm vasodilator capacity. Am. J. Cardiol.78(2), 208–211 (1996).
   PubMedGoogle Scholar
• Cardillo C, Kilcoyne CM, Cannon RO 3rd, Panza JA. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in Blacks as a cause of racial differences in vasodilator function. Circulation99(1), 90–95 (1999).
   PubMedGoogle Scholar
• Perragaux D, Chaudhuri A, Rao S et al. Brachial vascular reactivity in Blacks. Hypertension36(5), 866–871 (2000).
   PubMedGoogle Scholar
• Jones DS, Andrawis NS, Abernethy DR. Impaired endothelial-dependent forearm vascular relaxation in Black Americans. Clin. Pharmacol. Ther.65(4), 408–412 (1999).
   PubMed Web of Science ®Google Scholar
• Din-Dzietham R, Couper D, Evans G, Arnett DK, Jones DW. Arterial stiffness is greater in African–Americans than in Whites: evidence from the Forsyth County, North Carolina, ARIC cohort. Am. J. Hypertens.17(4), 304–313 (2004).
   PubMed Web of Science ®Google Scholar
• Lang CC, Stein CM, Brown RM et al. Attenuation of isoproterenol-mediated vasodilatation in Blacks. N. Engl. J. Med.333(3), 155–160 (1995).
   PubMedGoogle Scholar
• Weinberger MH. Pathogenesis of salt sensitivity of blood pressure. Curr. Hypertens. Rep.8(2), 166–170 (2006).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Svetkey LP, Vollmer WM et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N. Engl. J. Med.344(1), 3–10 (2001).
   PubMed Web of Science ®Google Scholar
• Pratt HJ. Central role for ENaC in development of hypertension. J. Am. Soc. Nephrology16(11), 3154–3159 (2005).
   PubMed Web of Science ®Google Scholar
• Pratt HJ, Ambrosius WT, Agarwal R, Eckert GJ, Newman S. Racial difference in the activity of the amiloride-sensitive epithial sodium channel. Hypertension40(6), 903–908 (2002).
   PubMed Web of Science ®Google Scholar
• Turner ST, Schwartz GL, Chapman AB, Boerwikel E. C825T polymorphism of the G-protein β3-subunit and antihypertensive response to a thiazide diuretic. Hypertension37(2 Pt 2), 339–743 (2001).
   Google Scholar
• Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in Blacks with heart failure. N. Engl. J. Med.351(20), 2049–2057 (2004).
   PubMed Web of Science ®Google Scholar
• Suthanthiran M, Li B, Song JO et al. Transforming growth factor-β1 hyperexpression in African–Americans hypertensive: a novel mediator of hypertension and/or target organ damage. Proc. Natl Acad. Sci. USA97(7), 3479–3484 (2000).
   PubMed Web of Science ®Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288(23), 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA290(21), 2805–2816 (2003).
   PubMed Web of Science ®Google Scholar
• Sehgal AR. Overlap between Whites and Blacks in response to antihypertensive drugs. Hypertension43(3), 566–572 (2004).
   PubMed Web of Science ®Google Scholar
• Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens.16(11), 925–930 (2003).
   PubMed Web of Science ®Google Scholar
• Saha C, Echert GJ, Ambrosius WT et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in Blacks with hypertension. Hypertension46(3), 481–487 (2005).
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American heart association professional education committee of the council for high blood pressure research. Hypertension51, 1403–1419 (2008).
   PubMed Web of Science ®Google Scholar
• Wright JT, Bakris G, Green T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK Trial. JAMA288(19), 2421–2431 (2002).
   PubMed Web of Science ®Google Scholar
• Kostis JB, Kim HJ, Rusnak J et al. Incidence and characteristics of angioedema associated with enalapril. Arch. Intern. Med.165(14), 1637–1642 (2005).
   PubMedGoogle Scholar
• Wright Jr JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive Black and nonBlack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA293(13), 1595–1608 (2005).
   PubMedGoogle Scholar
• Ferdinand KC. Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with omapatrilat, a vasopeptidase inhibitor. J. Clin. Hypertens.3(5), 307–312 (2001).
   Google Scholar
• Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359(9311), 1004–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet359(9311), 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Oh B, Mitchell J, Herron J et al. Aliskiren, an oral rennin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J. Am. Coll. Cardiol.49(11), 1157–1163 (2007).
   PubMed Web of Science ®Google Scholar
• Mason PR, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivollol reduces nitric stress and restores nitric oxide bioavailability in endothelium of Black Americans. Circulation112(24), 3795–3801 (2005).
   PubMed Web of Science ®Google Scholar
• Severs P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J. Renin Angiotensin Aldosterone Syst.7(2), 61–63 (2006).
   PubMedGoogle Scholar
• Haffner SM, Mitchell BD, Valdez RA et al. Eight-year incidence of hypertension in Mexican–Americans and non-Hispanic Whites. The San Antonio Heart Study. Am. J. Hypertens.5(3), 147–153 (1992).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Mitchell BD, Stern MP et al. Decreased prevalence of hypertension in Mexican–Americans. Hypertension16(3), 225–232 (1990).
   PubMed Web of Science ®Google Scholar
• Crespo CJ, Loria CM, Burt VL. Hypertension and other CVD risk factors among Mexican–Americans, Cuban Americans, and Puerto Ricans from the Hispanic Health and Nutrition Examination Survey. Public Health Rep.111(Suppl. 2), 7–10 (1996).
   PubMedGoogle Scholar
• Margolis KL, Piller LB, Ford CE et al. Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial collaborative research group. Hypertension50(5), 854–861 (2007).
   PubMedGoogle Scholar
• Venkataraman R, Nanda NC, Baweja G et al. Prevalence of diabetes mellitus and related conditions in Asian Indians living in the United States. Am. J. Cardiol.94(7), 977–980 (2004).
   PubMed Web of Science ®Google Scholar
• Woo J, Chan TY. A high incidence of cough associated with combination therapy of hypertension with isradipine and lisinopril in Chinese subjects. Br. J. Clin. Pract.45(3), 178–180 (1991).
   PubMedGoogle Scholar
• Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br. J. Clin. Pharmacol.40(2), 141–144 (1995).
   PubMed Web of Science ®Google Scholar
• Gupta R. Trends in hypertension epidemiology in India. J. Hum. Hypertens.18(2), 73–78 (2004).
   PubMed Web of Science ®Google Scholar
• Park IU, Taylor AL. Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann. Fam. Med.5(5), 444–452 (2007).
   PubMedGoogle Scholar
• Kjeldsen SE, Julius S, Brunner H et al. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. Blood Press.10(2), 83–91 (2001).
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg-Thurmond E, Marks RG et al. Rationale and design of the The International Verapamil SR/Trandolapril Study (INVEST): an internet-based randomized trial in cornary artery disease patients with hypertension. J. Am. Coll. Cardiol.32(5), 1228–1237 (1998).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363(9426), 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension34(5), 1129–1133 (1999).
   PubMed Web of Science ®Google Scholar
• Yui Y, Sumiyoshi T, Kodama K et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens. Res.27(3), 181–191 (2004).
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J. Hypertens.23(12), 2157–2172 (2005).
   PubMed Web of Science ®Google Scholar
• Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N. Engl. J. Med.345(7), 479–486 (2001).
   PubMed Web of Science ®Google Scholar
• Berlowitz DR, Ash AS, Hickey EC et al. Inadequate management of blood pressure in a hypertensive population. N. Engl. J. Med.339(2), 1957–1963 (1998).
   PubMed Web of Science ®Google Scholar
• Knight EL, Bohn RL, Wang PS. Predictors of uncontrolled hypertension in ambulatory patients. Hypertension38(4), 809–814 (2001).
   PubMed Web of Science ®Google Scholar
• Jackson JH 4th, Bramley TJ, Chiang TH et al. Determinants of uncontrolled hypertension in an African–Americans population. Ethn. Dis.12(4), S3–53–57 (2002).
   PubMedGoogle Scholar